MAT Resources

Out-of-hospital infusion services for COVID-19 patients

The Medical Advisory Team updates its recommendation regarding out-of-hospital infusion services to manage the risk of infusion reactions in patients treated with intravenous therapies for COVID-19 infection: Personnel providing infusion therapy for COVID-19 should...

REGN-COV2 treatment for COVID-19 patients in NM

Casirivimab and imdevimab (REGN-COV2), which is produced by Regeneron Pharmaceuticals, should be used for outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds) as soon as possible...

Convalescent Plasma Treatment for COVID-19 Patients

In August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for the treatment of hospitalized patients with COVID-19.The use of COVID-19 Convalescent Plasma (CCP) collected from individuals who...